Q3 2024 Earnings Forecast for Zynex, Inc. (NASDAQ:ZYXI) Issued By HC Wainwright

Zynex, Inc. (NASDAQ:ZYXI - Free Report) - Investment analysts at HC Wainwright boosted their Q3 2024 earnings estimates for Zynex in a research note issued on Wednesday, May 1st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $0.16 for the quarter, up from their prior estimate of $0.14. HC Wainwright has a "Buy" rating and a $21.00 price objective on the stock. The consensus estimate for Zynex's current full-year earnings is $0.50 per share. HC Wainwright also issued estimates for Zynex's Q4 2024 earnings at $0.26 EPS and FY2025 earnings at $0.85 EPS.

Zynex (NASDAQ:ZYXI - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.13). Zynex had a net margin of 4.33% and a return on equity of 16.34%. The business had revenue of $47.28 million during the quarter, compared to analyst estimates of $54.53 million. During the same period in the previous year, the company posted $0.20 earnings per share. Zynex's revenue was down 3.1% on a year-over-year basis.

Separately, Royal Bank of Canada upped their target price on Zynex from $13.00 to $15.00 and gave the stock an "outperform" rating in a research report on Friday, March 1st.

Zynex Trading Down 4.7 %

Shares of ZYXI traded down $0.54 on Friday, hitting $11.00. 100,924 shares of the stock traded hands, compared to its average volume of 230,960. The stock's 50 day moving average is $12.31 and its two-hundred day moving average is $10.84. The firm has a market capitalization of $349.47 million, a P/E ratio of 47.83 and a beta of 0.49. Zynex has a 1 year low of $6.88 and a 1 year high of $13.77. The company has a quick ratio of 4.03, a current ratio of 3.58 and a debt-to-equity ratio of 1.76.

Institutional Trading of Zynex

A number of institutional investors and hedge funds have recently modified their holdings of ZYXI. Principal Financial Group Inc. boosted its stake in Zynex by 56.4% in the first quarter. Principal Financial Group Inc. now owns 17,679 shares of the company's stock valued at $219,000 after acquiring an additional 6,378 shares during the period. Rice Hall James & Associates LLC increased its position in Zynex by 101.4% in the 1st quarter. Rice Hall James & Associates LLC now owns 242,557 shares of the company's stock valued at $3,000,000 after acquiring an additional 122,128 shares during the period. Bridge City Capital LLC lifted its stake in shares of Zynex by 4.1% in the 1st quarter. Bridge City Capital LLC now owns 186,665 shares of the company's stock worth $2,309,000 after acquiring an additional 7,270 shares during the period. Congress Asset Management Co. MA boosted its holdings in shares of Zynex by 1.0% in the first quarter. Congress Asset Management Co. MA now owns 118,376 shares of the company's stock valued at $1,464,000 after acquiring an additional 1,225 shares in the last quarter. Finally, Cim LLC acquired a new position in shares of Zynex during the fourth quarter valued at approximately $446,000. 29.68% of the stock is owned by institutional investors and hedge funds.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.